Misonix, a developer of minimally invasive therapeutic ultrasonic devices, received 510(k) FDA clearance for Nexus, its new integrated ultrasonic surgical platform.
Three key notes:
1. The Nexus platform is driven by a new proprietary digital algorithm that aims to increase power, efficiency and control.
2. The device seeks to improve resection rates and help surgeons perform more efficient bone removal procedures.
3. Misonix sees the new technology as a strategic growth opportunity. "Nexus is a key component of our strategy to increase our presence in the neuro, spine, ortho, wound and general surgery markets," said Stavros Vizirgianakis, president and CEO of Misonix.